Daming capsule combined with SGLT2i confers protection against diabetes with myocardial ischemia/reperfusion injury induced ferroptosis via AMPK

Figure 3 Daming capsule combined with sodium-dependent glucose transporters 2 inhibitor improved cardiac function and metabolism caused by diabetes mellitus with ischemia-reperfusion. A: Representative images of echocardiogram and ejection fraction, fractional shortening, left ventricular internal diameter at end-diastole and left ventricular internal diameter at end-systole were analyzed; B: Statistical analysis of fasting blood glucose; C: The activity of lactate dehydrogenase in serum; D: The content of total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein in serum; E: Representative images of hematoxylin and eosin staining, and representative images of masson staining and statistical graph. Above results are presented as the mean ± SD. The comparison between more groups was conducted by one-way analysis of variance. ^aP < 0.05 vs the NULL group (diabetes mellitus + ischemia-reperfusion model). DMC: Daming capsule; SGLT2i: Sodium-dependent glucose transporters 2 inhibitor; I/R: Ischemia-reperfusion; DM: Diabetes mellitus; LDL-c: Low-density lipoprotein cholesterol; LDH: Lactate dehydrogenase; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; TC: Total cholesterol; TG: Triglyceride; LVID;s: Left ventricular internal diameter at end-systole; LVID;d: Left ventricular internal diameter at end-diastole; HE: Hematoxylin and eosin.